Chinese biotech giant WuXi AppTec raises 2026 outlook after profit surge
WuXi AppTec raised its full-year revenue guidance after its net profit surged 62.4 per cent in the first nine months of 2026, while revenue rose 38.6 per cent on strong demand for its drug development and manufacturing services. The Chinese pharmaceutical research services provider’s net profit reached 19.16 billion yuan (US$2.87 billion) for the nine months ended September 30, compared with 11.80 billion yuan a year earlier, a filing to the Hong Kong stock exchange showed. Its revenue rose to...
How sure are we
2 outlets reported this story, but it isn’t verified yet: that takes two or more independent outlets and a reliability score of 65%.
Who reported it
[Claude] Back to pending: the other outlets reported a different event. Report 2 covers Computacenter's raised 2026 profit outlook, a separate company's news, though the headlines share wording.
3h agoScore bands
What moves the score
Not in the score: AI checks and reader flags. Verified is separate: two or more independent outlets and a score of at least 65%.
Very high · How we score this